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In Brief
The mood stabilizer lithium has been
shown to extend lifespan in organisms
ranging from yeast to flies. Castillo-Quan
et al. show that lithium promotes
longevity through GSK-3 inhibition and
subsequent NRF-2 activation, suggesting
that GSK3 is a possible drug target that
might affect aging.
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The quest to extend healthspan via pharmaco-
logical means is becoming increasingly urgent,
both from a health and economic perspective.
Here we show that lithium, a drug approved for
human use, promotes longevity and healthspan.
We demonstrate that lithium extends lifespan in
female and male Drosophila, when administered
throughout adulthood or only later in life. The life-
extending mechanism involves the inhibition of
glycogen synthase kinase-3 (GSK-3) and activation
of the transcription factor nuclear factor erythroid
2-related factor (NRF-2). Combining genetic loss
of the NRF-2 repressor Kelch-like ECH-associated
protein 1 (Keap1) with lithium treatment revealed
that high levels of NRF-2 activation conferred
stress resistance, while low levels additionally
promoted longevity. The discovery of GSK-3 as
a therapeutic target for aging will likely lead to
more effective treatments that can modulate
mammalian aging and further improve health in
later life.
INTRODUCTION
Lithium is the most commonly prescribed drug for the treatment
of bipolar disorder. It also improves disease phenotypes in
animal models of many clinical conditions including Alzheimer
disease, depression, and stroke (Chiu and Chuang, 2010). The
effects of lithium on aging have been documented in yeast and
Caenorhabditis elegans, with lithium extending lifespan (McColl
et al., 2008; Zarse et al., 2011; Tam et al., 2014; Sofola-Adesakin
et al., 2014). The effects of lithium on Drosophila aging have pre-
viously been inconclusive, with demonstration of both positive
and negative effects on survival (Matsagas et al., 2009; Zhu
et al., 2015). Moreover, lithium concentration in the drinking wa-638 Cell Reports 15, 638–650, April 19, 2016 ª2016 The Authors
This is an open access article under the CC BY license (http://creativeter of a large Japanese population has been associated with
reduced all-cause mortality (Zarse et al., 2011), suggesting that
lithium may be a bona fide anti-aging drug. However, the mech-
anisms by which lithium acts in humans remain poorly
understood.
In vitro studies have reported that lithium can protect against
several forms of oxidative and xenobiotic stressors (Lai et al.,
2006; Scha¨fer et al., 2004), but in vivo evidence for such pro-
tective effects of lithium is lacking. Longevity has been exten-
sively correlated with resistance to stress (Minois, 2000; Rattan,
2008; Calabrese et al., 2011; Epel and Lithgow, 2014). Tran-
scriptomic analysis of interventions known to extend lifespan
have identified particular genes likely to be involved in stress
resistance (McElwee et al., 2007; Steinbaugh et al., 2012). Up-
regulation of the transcription factor cap’n’collar C (CncC, an
NRF-2 homolog) has been shown not only to confer resistance
to toxic compounds, but also to promote longevity in C. ele-
gans and flies (Tullet et al., 2008; Sykiotis and Bohmann,
2008; Ewald et al., 2015). In flies and mammals, NRF-2/CncC
is negatively inhibited through cytosolic sequestration and pro-
teasomal degradation by the canonical Keap1 (Hayes and Din-
kova-Kostova, 2014; Pitoniak and Bohmann, 2015). However,
a second emerging upstream regulator of NRF-2/CncC is
GSK-3, a well-documented target of lithium (Jope, 2003; Hayes
and Dinkova-Kostova, 2014; Cuadrado, 2015; Hayes et al.,
2015; Blackwell et al., 2015). GSK-3 regulates NRF-2 by phos-
phorylation and nuclear exclusion, an effect that is evolution-
arily conserved from invertebrates to mammals (Salazar et al.,
2006; An et al., 2005). Interestingly, GSK-3 inhibition has
been shown to phenocopy the effects of lithium for protection
against xenobiotic stress in vitro (Lai et al., 2006; Scha¨fer
et al., 2004).
Activation of NRF-2/CncC produces hormetic effects on
lifespan, such that at low level NRF-2/CncC activity extends
lifespan while higher levels of activation limit it (Mattson,
2008; Maher and Yamamoto, 2010). Interestingly a hormetic
signature was recently reported for the survival of a mamma-
lian cell line treated with lithium (Suganthi et al., 2012),
suggesting that lithium and GSK-3 inhibition could influencecommons.org/licenses/by/4.0/).
AF
B
C D
E
G H
Figure 1. Lithium Regulated Longevity and
Metabolism in Drosophila
(A) Lithium extended lifespan of wDah Drosophila
females (n = 160 flies per condition) at concentra-
tions between 1 and 25 mM (+16% and +18%
median and maximum lifespan extension; p <
0.001), but resulted in a dose-dependent reduction
in lifespan at concentrations between 50 and
100 mM (p < 0.001).
(B) Lithium treated female w1118 flies showed a
significant improvement and protection against
age-related locomotor decline (p < 0.01, two-way
ANOVA for 10 mM).
(C) Lithium extended lifespan of aged, 32-day-old
female wDah flies at concentrations from 1 to
25 mM (30 days later than in Figure 1A): 1 mM
extended median lifespan by 5% (4 days) and
maximum lifespan by 13% (8 days; p < 0.05); 10
and 25 mM lithium increased median lifespan by
9% (6 days); 10 mM increased maximum lifespan
by 4.5% (3.5 days); wherease 25 mM lengthened it
by 8% or 6 days (p < 0.01); and 50 and 75 mM
significantly shortened lifespan (p < 0.01). n = 150
flies per condition.
(D) Brief treatment with lithium for 15 days early in
adulthood extended lifespan of female wDah flies
(p < 0.05 for 1 mM and p < 0.01 for 10 mM; n = 150
flies per condition).
(E) Lithium induced a dose-dependent reduction in
triglyceride levels. Bars represent means of six
replicas of five flies per condition ± SEM. *p < 0.01,
**p < 0.001.
(F) Female wDah flies pre-treated with lithium for
15 days were subsequently sensitive to starvation
in a dose-dependent manner (n = 90 flies per
condition).
(G) Lithium treatment significantly extended the
lifespan of w1118 female flies exposed to a four
times higher sucrose concentration (2g/L; p <
0.001; n = 120 flies per condition).
(H) The increase of triglycerides observed on a
high-sucrose diet was completely blocked after
15 days of treatment with 1 mM lithium. Bars
represent means of six replicas of fivew1118 female
flies per condition ± SEM. *p < 0.01.animal lifespan and stress resistance through activation of
NRF-2.
Here we show that lithium supplementation in the diet can
modulate longevity, stress resistance, and metabolism in
Drosophila through the inhibition of GSK-3. Correspondingly,
genetic downregulation of GSK-3 and lithium treatment are
epistatic, suggesting a common molecular pathway. We also
show that lithium and the genetic inhibition of GSK-3 promote
xenobiotic stress resistance and lifespan extension through
the activation of a transcriptional response mediated by
CncC/NRF-2. Furthermore, lithium protects against a high-su-
crose diet and acts through mechanisms that only partially
overlap with those mediating lifespan extension by dietary
restriction (DR). These findings demonstrate an alternative
genetic and pharmacological target for the promotion of
longevity and stress resistance, and emphasize the potential
of pharmacological inhibitors of GSK-3 as viable anti-aging
treatments.RESULTS
Lithium Extends Healthy Lifespan in Drosophila
To assess the role of lithium inDrosophila aging, we treated adult
female flies with lithium chloride (LiCl) by supplementation in
their food. Lithium treatment in the range of 1 to 25 mM resulted
in lifespan extension, whereas higher doses (50–100 mM) short-
ened lifespan (Figure 1A). These effects of lithium treatment on
lifespan extension were also observed in an independent genetic
background (Figure S1A) and inmales (Figure S1B). Thus, lithium
treatment extended Drosophila lifespan independently of ge-
netic background and sex.
To ensure that the increased lifespan observed with lithium
supplementation was dependent on the addition of lithium itself,
we treated flies with equivalent molar concentrations of sodium
chloride (NaCl) and found no lifespan extension (Figures S1C and
S1D). Thus, the pro-longevity effect of LiCl is specific to lithium
and not its chloride counterion.Cell Reports 15, 638–650, April 19, 2016 639
Interestingly, we observed that, unlike with many other genetic
and pharmacological interventions (e.g., DR, insulin/IGF down-
regulation, rapamycin, or trametinib treatment), lithium did not
reduce fecundity at life-extending doses or compromise feeding
behavior (Figures S1E and S1F). Moreover, it delayed locomotor
decline at two concentrations that extend lifespan (Figure 1B).
Thus, lithium promotes healthspan in adult Drosophila with
limited side effects.
Lithium Extends Lifespan in Mid-life or with Short-Term
Treatment in Young Flies
To limit the side effects of long-term use, a drug that improves
lifespan and healthspan will ideally do so with late-onset admin-
istration (Castillo-Quan et al., 2015; Longo et al., 2015). We
therefore assessed the effect of commencing lithium treatment
at older ages. Flies were switched onto food containing a range
of lithium concentrations (1–75mM) at 32 days of age (Figure 1C).
Lower doses (1–25 mM) of lithium extended lifespan, whereas
higher doses (50 and 75 mM) significantly reduced lifespan,
similar to the dose-dependent effects we observed in younger
flies.
We also tested whether transient lithium treatment early in life
could increase lifespan. We therefore exposed young flies to 1 or
10 mM lithium for 15 days and then switched them to control
food for the remainder of their lifespans. Early treatment with
these doses of lithium extended lifespan (Figure 1D). Lithium
treatment early in life, and for a transient period, can therefore in-
crease survival later in life.
Lithium Alters Lipid Metabolism and Promotes Survival
under a High-Sugar Diet
Genetic and environmental interventions that extend lifespan
often induce abnormalities in carbohydrate and lipid metabolism
(Barzilai et al., 2012;Wang et al., 2014; Lamming et al., 2013). We
therefore examined the effects of lithium on whole body treha-
lose, glycogen, and triglyceride levels. Following 15 days of
lithium treatment, and over a wide range of lithium concentra-
tions, we were unable to detect a significant change in the levels
of either trehalose or glycogen (Figures S1G and S1H). However,
we observed a dose-dependent reduction in whole body triglyc-
erides, themain lipid storage in flies (Ballard et al., 2008; Skorupa
et al., 2008) (Figures 1E and S1I). In keeping with the lowered tri-
glyceride levels (Ballard et al., 2008; Ulgherait et al., 2014),
lithium treatment reduced survival under starvation conditions
in a dose-dependent manner (Figures 1F and S1J). Moreover,
lithium also extended lifespan under dietary conditions that pro-
mote triglyceride accumulation (Skorupa et al., 2008). Flies fed a
high-sucrose diet were short lived and lithium was able to
partially rescue this defect (Figure 1G) while completely blocking
the increase in triglycerides observed with a sucrose-rich diet
(Figure 1H). Therefore, lithium can extend lifespan under obeso-
genic dietary conditions.
Lithium and DR Extend Lifespan via Partially
Overlapping Mechanisms
We next investigated whether lithium treatment was acting as a
DR mimetic. DR is a well-established anti-aging intervention
that extends healthy lifespan in diverse species (de Cabo et al.,640 Cell Reports 15, 638–650, April 19, 20162014; Fontana and Partridge, 2015), and some pharmacological
and genetic interventions that extend lifespan have features of
DR mimetics (Ingram and Roth, 2015; de Cabo et al., 2014). To
determine whether lithium and DR extend lifespan by similar
mechanisms, we assessedwhether lithium could extend lifespan
beyond the maximum achievable by DR. To maximize lifespan
under DR, we varied the yeast concentration in the food while
maintaining a constant concentration of sucrose (Bass et al.,
2007), resulting in a typical tent-shaped response, with peak life-
span at food containing a 1.0 yeast concentration (Figures 2Aand
S2A–S2D). If lithium treatment and DR share overlapping path-
ways, then lithium would not be able to further extend lifespan
already maximized by DR (Gems et al., 2002; Castillo-Quan
et al., 2015). All lithium doses tested significantly extended me-
dian lifespan in both the yeast condition that maximized lifespan
(1.0 yeast; Figures 2A and S2C) and under full feeding (2.0 yeast;
Figures 2A and S2D), with greatest extension of median lifespan
with 10 mM lithium under full feeding. However, under reduced
yeast concentrations that shorten lifespan (0.2 and 0.5 yeast),
10 mM lithium either significantly reduced lifespan (Figure S2B)
or did not confer a significant lifespan benefit (Figure S2A). Cox
proportional hazards analysis showed a significant interaction
between lithiumandyeast concentrations for lifespan (interaction
termp< 0.0001). The extension of lifespan from lithium increased
with the level of yeast in the fly diet, suggesting partially overlap-
ping mechanisms to those of DR.
Lithium Extends Lifespan through Inhibition of GSK-3
A well-known target of lithium is GSK-3 (Phiel and Klein, 2001;
Jope, 2003; Eldar-Finkelman and Martinez, 2011). We therefore
evaluated the phosphorylation status of the fly ortholog of
GSK-3, Shaggy (Sgg), in response to lithium treatment. Lithium
addition to the fly medium resulted in a dose-dependent in-
crease in the inhibitory phosphorylation (Serine 9 or S9) of Sgg
(Figure 2B). To evaluate the role of Sgg in lithium-mediated life-
span extension, we directly manipulated its activity in adult flies.
Ubiquitous overexpression of wild-type or constitutively active
Sgg (SggS9A) significantly reduced lifespan by 30% and
50%, respectively (Figures 2C and S2E). This reduction in life-
span was almost completely reversed by lithium treatment.
Furthermore, RNAi-mediated reduction in sgg expression using
two independent dsRNA-expressing transgenes significantly
increased lifespan (Figures 2D and S2F). Importantly, lithium
was unable to further increase the lifespan of these sgg RNAi
knockdownmutants flies (Figure 2D). Taken together, these find-
ings suggest that Sgg/GSK-3 inhibition and lithium treatment in-
crease lifespan by acting on the same downstream targets.
Lithium Activates the Cap’n’Collar C/NRF-2
Transcription Factor
To identify downstream mediators of lifespan extension by
lithium and of GSK-3 inhibition, we analyzed the genome-wide
transcript profiles of lithium-treated flies using microarrays.
Genes encoding ribosomal proteins were among the most upre-
gulated (Figure 3A) and downregulated (Figure S3A) gene
ontology (GO) categories in lithium-treated flies. This transcrip-
tional response could underlie the translational repression
following lithium treatment that has been previously observed
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Figure 2. Lithium Extended Lifespan beyond Dietary Restriction by Inhibiting Sgg/GSK-3
(A) Median lifespans at different lithium concentrations (0, 1, 2.5, 5, or 10 mM) are plotted for four different yeast concentrations (0.23, 0.53, 1.03, and 2.03
yeast): 1–5 mM lithium extended lifespan under all dietary conditions tested. Although 10 mM lithium prolonged life at 1.03 and 2.03, it showed no effect at 0.23
and significantly shortened lifespan at 0.53 yeast. *p < 0.05, **p < 0.01, ***p < 0.001, from 0 lithium; n = 160 flies per condition. Complete survival curves are shown
in Figures S2A–S2D.
(B) Lithium treatment for 15 days significantly increased the inhibitory phosphorylation of Sgg/GSK-3 in a dose-dependent manner. Bars represent means of
triplicates of ten flies per biological repeat ± SEM, *p < 0.05, **p < 0.01.
(C) Ubiquitous overexpression of wild-type sgg significantly shortened lifespan (p < 0.001) and this was partially rescued by lithium treatment at two concen-
trations (10 and 25 mM; p < 0.001). See Figure S2E for the interaction of sgg(S9A) and lithium treatment on lifespan.
(D) Ubiquitous RNAi-mediated downregulation of sgg extended lifespan (p < 0.001) and no further extension occurred when the flies were treated with 1 or 5 mM
lithium (p > 0.05), whereas 10 mM lithium treatment restored the lifespan to control levels (p > 0.05), and 25 mMwas significantly toxic (p > 0.05). See Figure S2F
for lifespan extension obtained with an independent RNAi line.
Cell Reports 15, 638–650, April 19, 2016 641
in fission yeast and Drosophila heads (Sofola-Adesakin et al.,
2014). In addition, five GO terms for genes encoding enzymes
in the detoxification pathway were also in the ten most upregu-
lated categories (Figure 3A).
The responses to xenobiotics and oxidative stress in
Drosophila are regulated by the transcription factors dFOXO,
CncC, and DHR96 (Salih and Brunet, 2008; Sykiotis and
Bohmann, 2010; Tullet, 2015; Hoffmann and Partridge, 2015;
Blackwell et al., 2015). We therefore assessed whether the tran-
scriptional responses to activation of these transcription factors
overlapped with that of lithium treatment. The transcriptomic
response to lithium did not overlap with that of dFOXO-depen-
dent or -independent transcriptional regulation downstream of
IIS (Figures S3B and S3C) (Alic et al., 2011). Furthermore,
although we detected a significant overlap in the transcriptional
signatures of lithium and DHR96 (King-Jones et al., 2006), they
did not share the same directionality (Figure S4). However, we
found a significant overlap (Figure 3B) between the genes that
were upregulated by lithium and cncC overexpression (Misra
et al., 2011), but not between genes downregulated by both
treatments (Figure S5A), suggesting that lithium might activate
a CncC transcriptional response downstream of GSK-3. The
barbiturate phenobarbital activates CncC and induces a similar
transcriptional response to that of cncC overexpression (Misra
et al., 2011). We therefore analyzed the overlap between the
transcriptional profiles induced by lithium and phenobarbital
treatment, and again found a significant overlap (Figure 3B) be-
tween upregulated, but not downregulated, genes (Figure S5B).
The genes upregulated in common between lithium treatment,
phenobarbital treatment and cncC overexpression (Figures 3B
and S5C) encoded enzymes that participate in all three phases
of xenobiotic metabolism (Figure 3C). To further confirm the acti-
vation of CncC by lithium, we used a previously generated CncC
reporter that responds to both chemical and genetic inducers of
CncC (Sykiotis and Bohmann, 2008). Flies carrying the GstD-
eGFP CncC reporter showed a dose-dependent increase in
GFP expression with increasing concentrations of lithium (Fig-
ure 3D). Taken together, our results suggest that lithium activates
CncC to upregulate the expression of genes in the detoxification
pathway.
Lithium Induces Lifespan-Extension, Hormesis, and
Protection against Xenobiotics via CncC-Dependent
Mechanisms
We next assessed whether CncC activity is required for the pro-
longevity effects of lithium. Ubiquitous, RNAi-mediated knock-
down of cncC expression blocked the lifespan extension of
1 to 10mM lithium, but was detrimental to survival in flies treated
with 25 mM lithium, the highest dose that extends lifespan under
basal conditions, albeit to a lesser extent (Figure 4A). Thus,
lithium treatment requires CncC activity to confer its longevity
benefits.
Because CncC/NRF-2 can induce hormesis (Mattson, 2008;
Maher and Yamamoto, 2010), we assessed whether lithium
can also do this. To test for a hormetic effect of lithium at low
doses, we pre-treated flies with a range of concentrations of
lithium and then challenged them with a toxic dose of 500 mM.
Most pre-treatment doses of lithium induced subsequent resis-642 Cell Reports 15, 638–650, April 19, 2016tance to the toxic dose (Figure 4B). To assess whether the hor-
metic response of lithium was mediated by CncC, we knocked
down expression of cncC using RNAi, and treated the flies with
1–25 mM lithium. Reduction in cncC expression completely
blocked the hormetic response induced by 10 mM lithium pre-
treatment, and significantly reduced the effect of 25 mM lithium
(Figure 4C).
We next assessed the ability of lithium pre-treatment to pro-
tect against other xenobiotics. Flies pre-treated with increasing
concentrations of lithium ranging from 1 to 100 mM were signif-
icantly resistant to a toxic concentration of phenobarbital, with
lithium doses between 1 and 75 mM almost doubling survival
(Figure 4D). Lower doses of lithium also protected against a toxic
dose of the anti-malarial drug, chloroquine (Figure S5D;
1–10 mM), and the pesticide paraquat (Figure 4E). Thus, low to
intermediate concentrations of lithium protect against xenobiotic
toxicity. To determine the role of CncC activity in lithium-medi-
ated protection against phenobarbital, we used RNAi to knock
down expression of cncC, which sensitized the flies to pheno-
barbital and completely abrogated the protection against pheno-
barbital afforded by lithium supplementation (Figure 4F). Thus,
CncC is at least partly responsible for the hormetic effect
induced by low-level treatment with lithium.
To confirm that Sgg, upstream of CncC, is also necessary for
the resistance to xenobiotic stress (Blackwell et al., 2015; Cua-
drado, 2015; Hayes et al., 2015), we assessed the effect of ubiq-
uitous overexpression of wild-type sgg or the constitutively
active Sgg(S9A) on xenobiotic resistance. Both significantly
sensitized flies to phenobarbital (Figures 5A and S5E). We
confirmed that sgg or sgg(S9A) overexpression regulated
CncC by showing significantly lower levels of MRP and keap1
(Figures 5B and S5F), both CncC target genes. Correspondingly,
RNAi-mediated knockdown of sgg resulted in resistance to
phenobarbital (Figure 5C), and paraquat (Figure S5G). An in-
crease of mRNA levels of cncC, keap1, and gstD2 confirmed
that CncC was active in sgg knockdown flies (Figure 5D). Thus,
increased Sgg activity sensitizes against xenobiotic stressors,
whereas its inhibition protects against them.
Lifespan and Stress Resistance Depend on the Degree
of Activation of CncC by Keap1 and Lithium Treatment
In addition to activating CncC by repressing Sgg/GSK-3, lithium
could potentially increase CncC activity by inhibiting its canoni-
cal repressor Keap1 (Cuadrado, 2015; Pitoniak and Bohmann,
2015). Hence, we analyzed the interaction between lithium treat-
ment and Keap1. Overexpression of Keap1, which inhibits CncC
activity in vivo (Sykiotis and Bohmann, 2008), was unable to
prevent the lifespan-extending properties of lithium (Figure 6A),
suggesting that the longevity effect of lithium treatment is inde-
pendent of Keap1. Next, we analyzed the interaction of loss of
Keap1 and lithium treatment. We generated a deletion of the
keap1 coding sequence by P-element-mediated male recombi-
nation using a previously described P-element insertion line
(Sykiotis and Bohmann, 2008) (Figure 6B). The keap1 deletion
(keap1Del) was homozygous lethal, but activated CncC 4-fold in
the heterozygous state, as measured by the CncC reporter (Fig-
ure 6C). Lithium treatment of the keap1Del flies further activated
CncC (Figure 6C). We next tested whether this effect on CncC
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Figure 4. Lithium-Induced Xenobiotic Resistance and Longevity Were Mediated by CncC
(A) Ubiquitous knockdown of cncC blocked lifespan extension by lithium.
(B) Pre-treatment with increasing concentrations of lithium protected against a subsequent toxic dose of lithium (500 mM; p < 0.01 for doses from 10 to 100 mM;
p < 0.05 for 1 mM).
(C) Ubiquitous downregulation of cncC blocked the protective effect of 10 mM lithium pre-treatment against a subsequent toxic dose and partially blocked the
protective effect of 25 mM lithium pre-treatment.
(D) 1 to 100 mM lithium pre-treatment protected against a 6% phenobarbital (p < 0.001 for all doses).
(E) Lithium pre-treatment (for 15 days) protected against the herbicide paraquat in a dose-dependent manner (p < 0.001 for all doses, with maximal protection at
50 mM).
(F) RNAi-mediated downregulation of cncC completely blocked the protective effect of lithium against phenobarbital.activation protected against paraquat and lithium toxicity.
keap1Del flies were significantly resistant to both paraquat and
lithium (Figures 6D and 6E), and pre-treatment with lithiumFigure 3. Lithium Activated a Transcriptional Response Similar to that
(A) Ten most significantly upregulated GO categories induced by lithium treatme
(B) Lithium treatment of w1118 females flies induced a transcriptional response
7.83 3 108) or phenobarbital treatment (p = 3.85 3 1014) (Misra et al., 2011
phenobarbital treatment and overexpression of cncC.
(C) Genes upregulated by lithium treatment mapped to the three phases of the x
(D) Lithium treatment ofwDah female flies upregulatedGst-Dprotein levels. Bars rep
644 Cell Reports 15, 638–650, April 19, 2016further protected them.We confirmed these findings using a pre-
viously described heterozygous loss-of-function mutation in the
keap1 gene (keap1EY5) (Sykiotis and Bohmann, 2008) (Figuresof CncC/NRF-2
nt of w1118 female flies. See Figure S3A for downregulated GO categories.
that significantly overlapped with that induced by cncC overexpression (p =
). Heatmap showing the 57 genes most significantly changed by lithium or
enobiotic detoxification pathway in flies.
resentmeans of triplicates of ten flies per condition±SEM. *p< 0.05, **p < 0.01.
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A Figure 5. Reduced Activity of GSK-3
Increased Resistance to Xenobiotics
(A) Ubiquitous overexpression of wild-type sgg
significantly (p < 0.05) reduced survival under
xenobiotic stress with phenobarbital. n = 75 flies
per condition.
(B) Overexpression of wild-type sgg significantly
reduced multidrug-resistance like protein 1
(MRP) mRNA levels (p < 0.05, paired t test),
whereas non-significant trends were detec-
ted for glutathione S transferase D2 (gstD2)
and cncC mRNA levels (p > 0.05). A non-sig-
nificant increase of keap1 mRNA levels was
observed.
(C) RNAi-mediated knockdown of sgg protected
against phenobarbital stress (p < 0.001). n = 75
flies per condition.
(D) Knockdown of sgg increased mRNA levels of
cncC, keap1 and gstD2 (p < 0.05), while a non-
significant increase was observed forMRPmRNA
levels.S6A and S6B). Thus, the combination of loss of keap1 and lithium
treatment further protected against paraquat and lithium-
induced toxicity, suggesting that stronger CncC activation re-
sults in greater protection against these xenobiotics.
We subsequently evaluated the interaction between loss of
keap1 and lithium treatment for longevity. Survival analysis
showed that the lifespan of keap1Del mutant flies was indistin-
guishable from controls, but that addition of 1 mM lithium
marginally, yet significantly, extended lifespan (Figure 6F).
Increasing the dose of lithium to 10 mM restored longevity to
control levels. The keap1EY5 mutant flies showed a significant
lifespan extension (Figure 6G). However, supplementation of
either 1 or 10 mM lithium to the keap1EY5 mutant shortened life-
span in a dose-dependent manner. These results suggest that
the level of activation of CncC that maximizes extension of life-
span is considerably lower than that which maximizes protection
against toxic doses of lithium and paraquat.
Lithium Does Not Induce or Require Autophagy to
Promote Longevity
Activation of autophagy has been proposed as a mechanism for
the beneficial effects of lithium (Sarkar et al., 2005). We therefore
analyzed the induction of autophagy by LC3-I/LC3-II (Atg8 in
Drosophila) levels without detecting statistically significant
changes. Indeed, there was a tendency for lower LC3-I that did
not reach statistical significance (Figure S7A). Moreover, lithium
treatment was able to extend the lifespan of flies with autophagy
defects due to heterozygous loss of atg1 (Figure S7B) (Lee et al.,
2007). Thus, taken together our results do not immediately sup-
port a role for autophagy in the pro-longevity effects of lithium
treatment, and strengthen our conclusion that they are mediated
through the inhibition of GSK-3 and the subsequent activation of
CncC/NRF-2 (Figure 7). However, it remains possible that induc-
tion of autophagy occurs in atg1-deficient flies, or that lithium in-
duces autophagy in a tissue-specific manner.DISCUSSION
Lithium Acts as a Pro-longevity Drug
Drug repurposing is themost promising approach for developing
pharmacological agents to improve healthy aging. So far, two
medically approved drugs, metformin and rapamycin, have
been reported to promote longevity and provide health benefits
across species from invertebrates to mammals (de Cabo et al.,
2014; Madeo et al., 2014; Riera and Dillin, 2015). We and others
have shown that lithium can extend lifespan in fission yeast,
C. elegans, and Drosophila (McColl et al., 2008; Matsagas
et al., 2009; Sofola-Adesakin et al., 2014). We also showed
that this effect was common between two different laboratory
strains and, unlike other interventions that seem to be more
effective in females (Austad and Bartke, 2015), lithium similarly
extended lifespan in both sexes.
Lifespan-extending drugs can often act like DR mimetics
(Madeo et al., 2014; Ingram and Roth, 2015); hence, it was
important to determine whether lithium was acting in a similar
manner. While low doses of lithium were able to extend life-
span at all dietary levels tested, median lifespan extension
was greatest under full feeding conditions. Our data thus sug-
gest that lithium and DR act via partially overlapping mecha-
nisms and confirms the observation made in C. elegans that
lithium extends lifespan of eat-2 mutants (McColl et al.,
2008), a genetic model of DR in worms. Lithium also extended
the lifespan of flies fed a diet enriched with sucrose, possibly
by modulating lipid metabolism (Sykiotis et al., 2011; Pang
et al., 2014; Karim et al., 2015; Steinbaugh et al., 2015).
However, the role of CncC in modulating the triglyceride
phenotype of lithium remains to be explored. Overall, our ob-
servations strongly suggest that lithium is a pro-longevity drug
capable of extending lifespan at low doses independent of sex
and genetic background, and under a variety of dietary
conditions.Cell Reports 15, 638–650, April 19, 2016 645
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Figure 6. Higher Activation Levels of CncC Promote Xenobiotic Resistance but Not Lifespan
(A) Overexpression of keap1 did not prevent the lifespan-modulatory effects of lithium treatment. n = 150 flies per condition.
(B) Schematic of the keap1 gene showing the portion deleted in the keap1Del mutant (top) and agarose gel showing start and end of P-element disrupting keap1
coding sequence in the keap1Del mutant (bottom).
(C) Combination of heterozygous deletion of keap1 and lithium treatment showed a greater activation of CncC than on their own. Bars represent means of four
replicas of five flies per repeat ± SEM. **p < 0.01.
(legend continued on next page)
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BA
Figure 7. Lithium Regulates Longevity, Metabolism, and Stress
Resistance by Inhibiting GSK-3 and Activating NRF-2
(A) Summary of findings with lithium for longevity, stress resistance, starvation,
and triglyceride levels.
(B) Proposed model showing the mechanism by which lithium, Sgg/GSK-3,
and CncC/NRF-2 act in the same pathway to modulate longevity and xeno-
biotic resistance.Lithium Toxicity, Hormesis, and Stress Resistance
In humans, the therapeutic window for lithium treatment of
bipolar disorder lies between 0.5 and 1 mM in serum, whereas
concentrations of 1.5 mM and above severely increase the risk
of tissue damage (Malhi and Tanious, 2011). Previous work in
Drosophila suggests that the dose range at which we observed
lifespan extension (0.5–25 mM) translates to Drosophila tissue
concentrations below0.5mM (Dokucuet al., 2005). Aspreviously
reported for C. elegans and Drosophila (McColl et al., 2008; Zhu
et al., 2015), concentrations above 50 mM were highly toxic.
Drug interventions to promote healthy lifespan are less likely to
have side effects if started late in life (Castillo-Quan et al., 2015).
Only a handful of drugs approved by the US Food and Drug(D) Deletion of keap1 in flies treated with lithium showed greater protection again
25 mM (p < 0.001).
(E) The keap1 deletion protected against toxic concentrations of lithium (500 mM
(F) Deletion of keap1 did not extend lifespan: 1mM lithium (p < 0.05), but not 10mM
n = 150 flies per condition.
(G) keap1EY5 mutant flies showed significant lifespan extension (p < 0.001), that w
activation of CncC. n = 150 flies per condition.Administration , namely rapamycin, metformin, and the Ras in-
hibitor trametinib, induce lifespan extension when commenced
at later ages in model organisms (Harrison et al., 2009; Cabreiro
et al., 2013; Martin-Montalvo et al., 2013; Slack et al., 2015). We
found that lithium extends lifespan when first administered in
mid-late life. In humans, long-term treatment with lithium for psy-
chiatric disorders is associated with progressive and permanent
renal damage (Malhi and Tanious, 2011). We showed that short
treatment periods in Drosophila, 15 days during early adulthood,
are sufficient to prolong life. Taken together, our data suggest
that when testing lithium as a pro-longevity drug in mammals,
lower doses than those used in psychiatric disorders are likely
to be sufficient, and other strategies such as alternate-day
dosing or transient treatment periods (either early or late in
life), may be sufficient to reduce undesirable side effects and
maximize the potential health benefits.
Interestingly, doses of lithium that shortened lifespan were
protective against certain forms of xenobiotic stress. In vitro
studies in mammalian cells have shown that lithium, and other
GSK-3 inhibitors, protect against cell death caused by rote-
none-induced oxidative stress (Lai et al., 2006), glutamate
excitotoxicity, and H2O2 (Scha¨fer et al., 2004). This is likely
mediated through a hormetic response (Suganthi et al., 2012),
in this case orchestrated by NRF-2 activation. We observed
that while simultaneous activation of CncC by loss of Keap1
and lithium treatment is additive and confers greater stress
resistance to xenobiotics, the threshold for lifespan extension
is perhaps considerably lower. A similar situation has been
observed in C. elegans in which strong activation of the endo-
plasmic reticulum unfolded protein response conferred stress
resistance benefits, while shortening lifespan (Taylor and Dillin,
2013). Our findings thus suggest that while NRF-2 activation
either by loss of Keap1 or inhibition of GSK-3 is beneficial for
longevity and stress resistance, at low levels of activation,
stronger induction is detrimental for lifespan. This suggests
that the hormetic benefits of lithium are more likely to occur
at low levels under basal non-stress conditions (Calabrese,
2013). Hence, when testing for GSK-3 inhibitors or NRF-2 acti-
vators in modulating animal (and especially mammalian) aging,
the degree of NRF-2 activation within the hormetic curve will
determine positive or negative longevity outcomes. Future
work studying the convergence of the salutary and damaging
effects of lithium will aid in understanding to what extent the
molecular mechanisms are shared (Calabrese and Mattson,
2011; Calabrese et al., 2013; Epel and Lithgow, 2014). Addi-
tionally, our microarray analysis was performed in heads and
thoraces; therefore, it remains to be explored to what extent
systemic or localized activation of NRF-2 modulates longevity,
stress resistance, and lipid metabolism at the tissue level
(Douglas et al., 2015).st paraquat than either treatment on its own, with maximal effects observed at
), and this protection was augmented with lithium pre-treatment (p < 0.01).
(p > 0.05), treatment of keap1 flies resulted in a small but significant extension.
as dose-dependently abolished (p > 0.05) by lithium, likely as a result of over-
Cell Reports 15, 638–650, April 19, 2016 647
GSK-3 and NRF-2 as Drug Targets for Aging
Complete absence of GSK-3 inC. elegans,Drosophila, andmice
shortens lifespan or prevents development (Hoeflich et al., 2000;
McColl et al., 2008; Bourouis, 2002), while moderate inhibition
has been associated with most of its positive effects (Avrahami
et al., 2013). GSK-3 is upregulated in many disease states,
including neurodegeneration, diabetes, inflammatory condi-
tions, and some cancers (Takahashi-Yanaga, 2013). We have
shown that adult-specific geneticmanipulation of the fly ortholog
of GSK-3, Sgg, affects longevity. Downregulation of Sgg pro-
longed lifespan and lithium was unable to further extend the life-
span, suggesting that lithium and inhibition of Sgg act through a
common molecular pathway to extend lifespan.
In C. elegans and mammalian cells, GSK-3 directly interacts
with NRF-2 to repress its activity, independently of Keap1 (An
et al., 2005; Salazar et al., 2006; Rojo et al., 2008; Rada et al.,
2012). Therefore, we hypothesized that lithium might act via
Sgg/GSK-3, to de-repress CncC, the fly ortholog of NRF-2 and
activate the oxidative and xenobiotic stress transcriptional
signature (An et al., 2005; Hayes et al., 2015), which in turn would
induce a CncC/NRF-2-dependent protective response (Jones
et al., 2015; Blackwell et al., 2015). GO enrichment analysis iden-
tified a transcriptional signature that indeed suggested that
lithium acts via CncC/NRF-2. CncC activity was indispensable
for the lifespan extension conferred by lithium. In keeping with
our results, work in rodents and mammalian cell lines has shown
that lithium treatment and GSK-3 inhibition activate NRF-2 (Lee
et al., 2014; Rizak et al., 2014). Because activation of CncC/
NRF-2 modulates longevity in C. elegans and Drosophila (Tullet
et al., 2008; Sykiotis and Bohmann, 2008; Ewald et al., 2015),
our results provide evidence that GSK-3 is a viable therapeutic
target to promote longevity via activation of NRF-2.
To date, the only GSK-3 inhibitor approved for human use is
lithium (Williams and Harwood, 2000; Meijer et al., 2004; Marti-
nez et al., 2011). However, researchers and pharmaceutical
companies have developed more selective GSK-3 inhibitors,
some of which have already entered the early stages of clinical
trials for obesity, Alzheimer disease, and progressive supranu-
clear palsy (Eldar-Finkelman and Martinez, 2011). Our results
call for a reassessment of the potential use of GSK-3 inhibitors
and NRF-2 activators as potential anti-aging compounds.
EXPERIMENTAL PROCEDURES
Fly Stocks and Husbandry
The w1118 stock was obtained from Bloomington Drosophila Stock Center.
The control white Dahomey (wDah) stock has been maintained in large popu-
lation cages with overlapping generations since 1970. The wDah stock was
initially derived by incorporation of the w1118 mutation into the outbred
Dahomey background by backcrossing (Bass et al., 2007). Further details
concerning fly mutants can be found in the Supplemental Experimental
Procedures.
Lithium Treatment
LiCl (Sigma) or NaCl (Sigma) were dissolved in ddH2O at a concentration of 5M
before supplementing to the medium. Equivalent volumes of vehicle were
supplemented to the medium to compensate for dilution.
Dietary Restriction Protocol
The DR protocol was performed as described previously (Bass et al., 2007).648 Cell Reports 15, 638–650, April 19, 2016Statistical Analyses
Statistical analyses were performed using Excel, GraphPad Prism, or JMP
software version 9 (SAS Institute). Survival experiments were analyzed using
log rank test. Other data were tested by one-way analyses of variance
(ANOVA) and planned comparisons of means were made using Tukey-Kramer
HSD test. Cox proportional hazards analysis was performed to compare inter-
actions for survival.ACCESSION NUMBERS
The accession number reported for the microarray data in this paper is
ArrayExpress: E-MTAB-3809.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.03.041.
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